Cilgavimab and Tixagevimab are given as injections by a healthcare professional in a clinical setting. Here’s how they are typically administered:

1. Injection Procedure: The two drugs are given as separate injections into a muscle, usually in the upper arm. Each injection is given slowly and carefully by a healthcare provider to avoid any complications.
2. Monitor for Reactions: After the injections, the patient is usually monitored for about 15-30 minutes to make sure there are no immediate allergic reactions or side effects. This is a routine procedure for all monoclonal antibody treatments.
3. Preparation: The medications are prepared by the healthcare provider just before the injection. The healthcare provider will ensure that the medications are in the correct form and are administered in the right amount.
4. Post-injection Care: You may be asked to rest for a while after receiving the injections to ensure no adverse effects develop. If you feel unwell after the injection, you should inform your healthcare provider immediately.

Cilgavimab and Tixagevimab are designed to mimic the body’s natural antibodies. Our immune system produces antibodies when it detects harmful invaders like viruses. These monoclonal antibodies work by binding to the spike protein on the surface of the SARS-CoV-2 virus. The spike protein is essential for the virus to enter human cells. When the antibodies attach to the spike protein, they prevent the virus from attaching to and entering the cells in the body.

This action stops the virus from multiplying and spreading, which helps the immune system fight off the infection. These two antibodies work together to enhance the overall effectiveness of the treatment. They can help prevent infection in people who are at higher risk of severe illness or who have weakened immune systems and may not respond well to the COVID-19 vaccine.

Like all medications, Cilgavimab and Tixagevimab can cause side effects. While not everyone will experience them, it’s important to be aware of potential reactions:

1. Allergic Reactions: Some people may have allergic reactions, which can range from mild symptoms such as a rash to more serious reactions, including difficulty breathing or swelling of the face and throat. Immediate medical attention is required if these symptoms occur.
2. Injection Site Reactions: Pain, swelling, redness, or irritation at the injection site are common and usually mild. These reactions typically go away after a few hours or days.
3. Headache: Some people may experience headaches following the injection, which may last for a short period of time.
4. Fatigue: Tiredness or feeling weak may occur, although it is usually temporary and goes away after a short period of rest.
5. Nausea or Diarrhea: Some people may feel mild stomach discomfort, such as nausea or diarrhea, after receiving the medication.
6. Fever or Chills: A low-grade fever or chills may occur, but these usually go away on their own within a day or two.
7. Infections: Because the treatment works by affecting the immune system, it may slightly increase the risk of infections. It is essential to monitor for symptoms of infection after treatment.

If you experience any of these side effects or anything unusual after the injection, you should contact your healthcare provider immediately for guidance.

Before receiving Cilgavimab and Tixagevimab, there are some important warnings and precautions to consider:

1. Allergic Reactions: If you have a history of severe allergies to monoclonal antibodies or any of the ingredients in this treatment, inform your healthcare provider. Severe allergic reactions, although rare, can be life-threatening.
2. Not for Treatment of Active COVID-19: These medications are used for prevention of COVID-19 and are not designed to treat an active infection. If you are already infected with the virus, these medications will not help.
3. Immunocompromised Patients: If you have a weakened immune system, such as from cancer treatments or certain diseases, Cilgavimab and Tixagevimab may be appropriate for preventing infection. However, your healthcare provider will assess the benefits and risks before proceeding with treatment.
4. Pregnancy and Breastfeeding: If you are pregnant or breastfeeding, talk to your doctor before receiving Cilgavimab and Tixagevimab. The safety of these medications during pregnancy and breastfeeding has not been fully established, so a healthcare provider will weigh the risks and benefits.
5. Monitor for Side Effects: You will be monitored after the injection for signs of allergic reactions or other complications. If you experience any side effects, especially breathing difficulties or severe allergic reactions, seek emergency medical help immediately.

Cilgavimab and Tixagevimab are monoclonal antibodies, and they may interact with other medications that affect the immune system or other treatments for COVID-19. These interactions can either reduce the effectiveness of the treatment or increase the risk of side effects. Some possible interactions include:

1. Other COVID-19 Treatments: Certain antiviral medications or vaccines may have interactions with monoclonal antibodies, though research is ongoing to determine how these treatments work together.
2. Immunosuppressive Drugs: Medications that weaken the immune system, such as corticosteroids or other immune-modulating drugs, may affect how the body responds to the treatment.

It’s important to tell your doctor about all other medications or supplements you are taking before receiving Cilgavimab and Tixagevimab. Your healthcare provider will help you manage any potential interactions.

The recommended dosage for Cilgavimab and Tixagevimab is:

• 300 mg of Cilgavimab and 300 mg of Tixagevimab as a one-time dose given as two separate injections (600 mg total).
• Frequency of administration: The dose is generally given as a one-time injection. For individuals who are at ongoing high risk, doctors may recommend repeating the dose at regular intervals (e.g., every few months), but this will be determined by your healthcare provider based on your individual risk factors.

It’s crucial to follow your healthcare provider’s instructions regarding the timing and dosage of the injections.

Cilgavimab and Tixagevimab are prescription medications. They must be prescribed by a healthcare provider who will determine if this combination treatment is appropriate for your individual situation. These medications are typically administered in a clinical setting, where the healthcare team can monitor for side effects and provide support if needed.

1. What are Cilgavimab and Tixagevimab?
   Monoclonal antibodies used for COVID-19 prevention and treatment.

2. What drug class do Cilgavimab and Tixagevimab belong to?
   Monoclonal antibody combination.

3. Are Cilgavimab and Tixagevimab controlled substances?
   No, they are not controlled substances.

4. Are there generic versions of Cilgavimab and Tixagevimab?
   No generics available; biologics are brand-specific.

5. What are common brand names for Cilgavimab and Tixagevimab?
   Evusheld.

6. What is the primary use of Cilgavimab and Tixagevimab?
   Pre-exposure prophylaxis for COVID-19 in high-risk individuals.

7. How are these medications administered?
   Intramuscular injection.

8. Is a prescription required for Cilgavimab and Tixagevimab?
   Yes, prescription and healthcare provider administration.

9. Who can benefit from Cilgavimab and Tixagevimab?
   Immunocompromised or individuals unable to get COVID-19 vaccines.

10. What are possible side effects?
    Injection site reactions, headaches, fatigue.

11. Can Cilgavimab and Tixagevimab be used together?
    Yes, they are given as a combination therapy.

12. Are there any drug interactions?
    Limited known interactions, but always check with a healthcare provider.

13. How long does protection last after administration?
    Generally around 6 months.

14. Can pregnant or breastfeeding women use these medications?
    Use only if benefits outweigh risks; consult a healthcare provider.

15. How is Cilgavimab and Tixagevimab stored?
    Refrigerated between 2°C and 8°C (36°F and 46°F).

16. Are these medications effective against all COVID-19 variants?
    Efficacy may vary with variants; ongoing evaluations.

17. Can these drugs be used for COVID-19 treatment?
    Primarily used for prevention but may have treatment roles under guidance.

18. What monitoring is required after administration?
    Observe for allergic reactions or adverse events.

19. Are Cilgavimab and Tixagevimab available worldwide?
    Availability depends on regulatory approvals per country.

20. Where can Cilgavimab and Tixagevimab be obtained?
    Administered in healthcare settings by authorized providers.